The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Inclusion Criteria Patients must have: HIV seropositivity. Average CD4 count between 50 and 500 cells/mm3 based on 2 separate pre-study determinations at least 1 week apart. Note: Patients with known hemophilia may be enrolled at the discretion of the investigator. Prior Medication: Excluded: Any protease inhibitor. Significant prior use (greater than 2 weeks) of nucleoside analogues. Chronic therapy for an active opportunistic infection. (Allowed: Prophylaxis with aerosolized pentamidine, trimethoprim/sulfamethoxazole, dapsone, topical antifungals, and isoniazid). Investigational agents or immunomodulators within 30 days prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Acute hepatitis. Lymphoma. Visceral Kaposi's sarcoma. Invasive cervical cancer. Active infection. Concurrent Medication: Excluded: Anticipated immunosuppressive therapy.